Barclays analyst Leon Wang downgraded CinCor Pharma (CINC) to Equal Weight from Overweight with a price target of $31, up from $22, after the company enter into an agreement to be acquired by AstraZeneca (AZN). The anlayst thinks the contingent value right is worth $5 per share.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CINC: